[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":66,"collaborators":10,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Methodist Health System","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treated w PRRT",null,"Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.",[13],"Procedure: Peptide Receptor Radionuclide Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Peptide Receptor Radionuclide Therapy","a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs",[9],[21],{"name":22,"affiliation":23,"role":24},"Alejandro Mejia, MD","Liver Institute at Methodist Dallas Medical Center","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Colette N Ndjom, MS","CONTACT","214-947-1280","clinicalresearch@mhd.com",{"name":32,"role":28,"phone":29,"phoneExt":33,"email":30},"Jennifer Kirchner","74459",[35,60],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Clinical Research Institute at Methodist Health System","RECRUITING","Dallas","Texas","75203","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-96.80667,32.78306,{"lat":47,"lon":46},[50,54,59],{"name":27,"role":28,"phone":51,"phoneExt":52,"email":53},"410-947-4681","74681","ColetteNgoNdjom@mhd.com",{"name":55,"role":28,"phone":56,"phoneExt":57,"email":58},"Loretta W Bedell, MPH","214-947-4680","74680","lorettabedell@mhd.com",{"name":22,"role":24,"phone":10,"phoneExt":10,"email":10},{"facility":61,"status":62,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":63,"geoPoint":65,"contacts":10},"Methodist Dallas Medical Center","ENROLLING_BY_INVITATION",{"type":44,"coordinates":64},[46,47],{"lat":47,"lon":46},{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100369414","peptide-receptor-radionuclide-therapy-prrt-for-the-treatment-of-neuroendocrine-tumors-100369414",false,"NCT04090034","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors","Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine","PRRT","Inclusion Criteria:\n\n1. \\> 18 years of age\n2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:\n\n   * Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.\n   * Metastatic or Locally Advanced AND Inoperable\n   * Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)\n   * Presence of disease within 24 weeks as identified by PET\u002FCT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and\u002For PET\u002FCT scans with FDG for transformation to high-grade NET\n   * Well differentiated on path - Ki67 \\\u003C 20%\n   * Octreotide positive on pathology (if not documented, acceptable if PET\u002FCT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:\n\n     * Cr. \\\u003C1.7\n     * Hgb \\>8\n     * WBC \\>2K\n     * Plt \\>75K\n     * Bili \\\u003C 3x normal limit\n   * No Octreotide within 30 days of administration.\n3. Willing and able to comply with the protocol requirements\n4. Able to comprehend and sign the Informed Consent Form in English.\n\nExclusion Criteria:\n\n* Do not meet the Study Inclusion Criteria laid out in section 6.3","ALL","18 Years",{"count":79,"type":80},50,"ESTIMATED","OBSERVATIONAL","The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.",[84,85],"Neuroendocrine Tumors","Gastroenteropancreatic Neuroendocrine Tumor","2026-03-18",{"date":88,"type":89},"2026-03-20","ACTUAL",{"date":91,"type":89},"2024-03-28",{"date":93,"type":80},"2026-06-28",{"name":5,"class":6},2]